John Lu

Shi-Jiang (John) Lu is the President and CEO of HebeCell. Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which in 2016 was acquired by Astellas, the second-largest pharmaceutical company in Japan. John is an expert in stem cell biology and regenerative medicine, with 20 years of experience in the field. John has been conducting translational research and developing novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. His goal is to generate hESC/iPSC-derived products to treat disease in humans. John also has extensive experience in the development and large-scale production of iPSC derivatives for clinical applications. John received his Ph.D. in Oncology and Cancer Biology from University of Toronto/Ontario Cancer Institute. He also holds an M.P.H. from Columbia University, an M.S. in Oncology from Peking Union Medical College, and a B.S. in Biochemistry from Wuhan University.